Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Get the annual and quarterly balance sheet of KalVista Pharmaceuticals, Inc. (KALV) including details of assets, liabilities and shareholders' equity.

Review the current KalVista Pharmaceuticals Inc (KALV:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if KALV is the best investment for you.

We just received data on a new analyst forecast for $KALV. Andrew Fein from HC Wainwright & Co. set a price target of 27.0 for KALV.

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

KalVista Pharmaceuticals, Inc. (KALV) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Check out our KALV stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Detailed price information for Kalvista Pharmaceuticals Inc (KALV-Q) from The Globe and Mail including charting and trades.

Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this ...